Purchase Order 75F40120P00532
Award Date
9/3/20
Potential Completion Date
12/11/22
Potential Value
$104K
Federal Agency
Food and Drug Administration
Awardee
CN Bio Innovations LIMITED
Ultimate Awardee
Not listed
NAICS Category
541511 - Custom Computer Programming Services
PSC Category
6640 - Laboratory Equipment And Supplies
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Available for Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Laurel, MD, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>The U.S. Defense Health Agency awarded a $212,610.00 firm fixed price purchase order contract to CN Bio Innovations LIMITED, a for-profit organization located in Great Britain, United Kingdom. The contract, which does not have a set-aside designation, is for the delivery of a PHYSIOMIMIX OOC MULTI-ORGAN STANDARD SYSTEM. The contract has an ultimate completion date of October 14, 2026.</p>
This is a $79,500 firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA), a civilian agency, to Nortis Inc., a for-profit manufacturer of biotechnology products and services. The contract is for the provision of a Parvivo System, which is an organ-on-a-chip technology. The contract has no set-aside designation and was awarded in September 2020, with a completion date of September 2021. Nortis Inc. has received prior federal grant awards from agencies such as...
This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services (HHS), to Emulate Inc., a for-profit small business. The contract, valued at $145,260.00, is for the delivery of Emulate's CHIP-S1 Stretchable Chip, a product in their organ-on-a-chip technology line. This technology supports various FDA and HHS initiatives in areas such as personalized medicine, biosurveillance, infectious disease...
The U.S. Food and Drug Administration (FDA) awarded a $42,455 firm-fixed-price purchase order to Fluigent, Inc., a foreign-owned for-profit organization, for the procurement of microfluidic equipment for organ-on-a-chip studies. This contract, awarded on July 13, 2024, has a completion date of July 14, 2025 and was not set aside for any specific business category. Fluigent, Inc. is a specialized provider of microfluidic solutions, including automated perfusion systems, pressure generators, and...
This firm-fixed-price purchase order was awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Emulate Inc. (doing business as Emulate) on June 1, 2020. The $130,163.45 contract, titled "EMULATE: ESTABLISHING ORGAN-CHIP MODELS FOR STUDYING RADIATION-INDUCED NORMAL TISSUE INJURY AND IDENTIFYING RNA BIOMARKERS FOR RADIATION BIODOSIMETRY," is for the development of an automated microfluidic cell culture system of human...
This is a $142,686.37 firm fixed-price purchase order contract awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to Emulate Inc. (doing business as Emulate), a for-profit small business. The contract is for Emulate's human emulation organ-on-a-chip instruments and accessories, which support the National Institute of Neurological Disorders and Stroke's mission to develop in vitro 3D brain organoid models for studying neurological...
This is a firm-fixed-price purchase order award by the Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI) to Emulate Inc., doing business as Emulate, a for-profit organization. The contract is a Total Small Business Set-Aside with a potential value of $204,922.00 and a completion date of March 19, 2024. The award is based on a combined synopsis/solicitation for Emulate Bio Organ-On-AChip reagent kits. Emulate's organ-on-a-chip...
This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the Department of Health and Human Services (HHS), to Mimetas Operations US, Co., a foreign-owned, self-certified small disadvantaged business. The $150,480.00 contract is for the acquisition of Organoplate Grafts, which are microfluidic 3D cell culture plates used in scientific research projects related to SARS-CoV-2 and COVID-19. This contract was...
The U.S. Food and Drug Administration (FDA) awarded a $120,950.00 firm fixed-price purchase order contract to Tissuse GMBH, a for-profit organization based in Germany. The contract is for the development of a multi-organ human-on-a-chip system, with a period of performance ending on December 31, 2024. The contract does not have a set-aside designation. Based on the FDA's role in evaluating medical technologies, this contract is likely related to the agency's efforts to advance the development of...
This is a $21,710 firm-fixed-price purchase order awarded by the National Cancer Institute, a civilian agency under the Department of Health and Human Services, to Fluigent, Inc., a foreign-owned for-profit organization. The contract is for the delivery of an ARIA Automated Perfusion System, a specialized microfluidic equipment used in advanced scientific research, with a performance period ending on May 27, 2025. The award is not associated with any set-aside program. Fluigent, Inc. has an...